EICHOR
● Active Not Recruiting
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Condition: Perennial Allergic Rhinitis (PAR) · Sponsor: Eli Lilly and Company
About this study
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (74)
| Allergy and Asthma Specialists Medical Group | Huntington Beach, California, United States | — |
| 310 Clinical Research | Inglewood, California, United States | — |
| Allergy & Asthma Associates of Southern California dba. Southern California Research | Laguna Niguel, California, United States | — |
| Allergy and Asthma | San Diego, California, United States | — |
| Asthma and Allergy Associates, PC | Colorado Springs, Colorado, United States | — |
| Allergy and Asthma Diagnostic Center | Tallahassee, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Asthma Allergy Center of Chicago | River Forest, Illinois, United States | — |
| Bluegrass Allergy Research | Lexington, Kentucky, United States | — |
| Respiratory Medicine Research Institute of Michigan, PLC | Ypsilanti, Michigan, United States | — |
| Clinical Research Institute | Minneapolis, Minnesota, United States | — |
+ 62 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06339008